|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002598,
umls-concept:C0008976,
umls-concept:C0011065,
umls-concept:C0018801,
umls-concept:C0030705,
umls-concept:C0085298,
umls-concept:C0162589,
umls-concept:C0205360,
umls-concept:C0936012,
umls-concept:C1513371,
umls-concept:C1696465
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2009-12-1
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces all-cause mortality in patients with New York Heart Association class II/III heart failure and a left ventricular ejection fraction < or =35% on optimal medical therapy. Whether ICD therapy reduced sudden death caused by ventricular tachyarrhythmias without affecting heart failure deaths in this population is unknown.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:AndersonJillJ,
pubmed-author:BardyGust HGH,
pubmed-author:BernsteinRobert CRC,
pubmed-author:BoehmerJohn PJP,
pubmed-author:CarlsonMark DMD,
pubmed-author:FrantzRobert PRP,
pubmed-author:HellkampAnne SAS,
pubmed-author:JohnsonGeorge WGW,
pubmed-author:LeeKerry LKL,
pubmed-author:MarkDaniel BDB,
pubmed-author:McNultySteve ESE,
pubmed-author:MitchellL BrentLB,
pubmed-author:PackerDouglas LDL,
pubmed-author:PooleJeanne EJE,
pubmed-author:PrutkinJordan MJM,
pubmed-author:RogersJoseph GJG,
pubmed-author:WalshMary NorineMN,
pubmed-author:WoodFredaF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
120
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2170-6
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:19917887-Amiodarone,
pubmed-meshheading:19917887-Anti-Arrhythmia Agents,
pubmed-meshheading:19917887-Cause of Death,
pubmed-meshheading:19917887-Combined Modality Therapy,
pubmed-meshheading:19917887-Death, Sudden, Cardiac,
pubmed-meshheading:19917887-Defibrillators, Implantable,
pubmed-meshheading:19917887-Follow-Up Studies,
pubmed-meshheading:19917887-Heart Failure,
pubmed-meshheading:19917887-Humans,
pubmed-meshheading:19917887-Kaplan-Meier Estimate,
pubmed-meshheading:19917887-Placebos,
pubmed-meshheading:19917887-Proportional Hazards Models,
pubmed-meshheading:19917887-Risk Factors,
pubmed-meshheading:19917887-Tachycardia
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
|
|
pubmed:affiliation |
Mayo Clinic, St. Mary's Hospital, Rochester, MN 55902, USA. packer@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
